ArticleJournal of computer-aided molecular design2026
TRIZ-guided computational innovation framework for the automated generation and prioritization of novel azole-like antifungal candidates targeting Candida auris CYP51.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The rising incidence of antifungal resistance has underscored the need for novel strategies that can expedite the discovery of structurally diverse and optimized antifungal candidates. Conventional approaches to modify azoles are limited by narrow chemical space and problems related to resistance with the fungal CYP51 (Eeg11). The objective of this study was to develop a TRIZ-guided computational framework for unbiased generation, prioritization and evaluation of novel azole-like antifungal candidates targeting fungal CYP51. A set of TRIZ inventive principles was translated into medicinal chemistry-guided structural modification rules, to build a Python-based molecular design workflow. The workflow produced a virtual library of seventy azole-like candidates that were computationally filtered and ranked without manual candidate selection. The top-ranked candidates were subjected to a combined in silico pipeline involving SwissDock-based molecular docking against a heme-containing holo-Candida auris CYP51 model, ligand efficiency analysis, SwissADME pharmacokinetic prediction, RDKit-based quantitative estimate of drug-likeness (QED), ProTox-3.0 toxicity profiling, molecular interaction analysis, target-space profiling, and ASKCOS retrosynthetic assessment. The automated TRIZ-guided approach could generate azole-like scaffolds with chemical relevance for ready downstream evaluation. The most promising compound identified from the screening of the candidates was AZ-TRIZ-02, which showed better predicted binding affinity to CYP51 than fluconazole. Ligand efficiency analysis showed greater binding contribution per heavy atom, implying that the improved interaction was not due to increased molecular size. AZ-TRIZ-02 also showed good drug-like attributes, the pharmacokinetic properties were acceptable, and the preliminary toxicity profile was free of the hepatotoxicity, mutagenicity, carcinogenicity, and cytotoxicity alerts. Interaction analysis confirmed stable placement within the CYP51 catalytic pocket. Retrosynthetic assessment supported theoretical synthetic feasibility. The work shows the potential of TRIZ-guided innovation, cheminformatics and AI-assisted molecular design combined as a reproducible framework for antifungal lead discovery. Future studies will be necessary to confirm the translational potential of the identified candidate, including experimental synthesis and antifungal testing, CYP51 inhibition assays and overall safety assessment.
Indexed as
Identifiers
42678629What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.